Insider Selling: Privia Health Group (NASDAQ:PRVA) CFO Sells 6,391 Shares of Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 6,391 shares of Privia Health Group stock in a transaction on Monday, March 16th. The shares were sold at an average price of $22.11, for a total transaction of $141,305.01. Following the completion of the transaction, the chief financial officer owned 220,413 shares in the company, valued at approximately $4,873,331.43. This trade represents a 2.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

David Mountcastle also recently made the following trade(s):

• On Friday, March 13th, David Mountcastle sold 6,565 shares of Privia Health Group stock. The shares were sold at an average price of $21.52, for a total transaction of $141,278.80.
• On Thursday, March 12th, David Mountcastle sold 6,453 shares of Privia Health Group stock. The stock was sold at an average price of $21.90, for a total value of $141,320.70.
• On Monday, March 9th, David Mountcastle sold 5,829 shares of Privia Health Group stock. The shares were sold at an average price of $22.84, for a total value of $133,134.36.
• On Friday, March 6th, David Mountcastle sold 5,177 shares of Privia Health Group stock. The shares were sold at an average price of $23.15, for a total value of $119,847.55.
• On Thursday, February 26th, David Mountcastle sold 5,361 shares of Privia Health Group stock. The stock was sold at an average price of $25.00, for a total value of $134,025.00.
• On Friday, February 27th, David Mountcastle sold 7,697 shares of Privia Health Group stock. The stock was sold at an average price of $25.05, for a total value of $192,809.85.

Privia Health Group Stock Down 2.3%

Shares of NASDAQ PRVA traded down $0.51 during midday trading on Wednesday, hitting $21.59. The stock had a trading volume of 1,112,897 shares, compared to its average volume of 813,190. Privia Health Group, Inc. has a 1-year low of $18.77 and a 1-year high of $26.51. The company has a market capitalization of $2.67 billion, a price-to-earnings ratio of 127.00, a PEG ratio of 1.38 and a beta of 0.82. The company has a fifty day moving average price of $22.80 and a 200 day moving average price of $23.61.

Privia Health Group (NASDAQ:PRVA) last posted its earnings results on Thursday, February 26th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.21. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The firm had revenue of $541.17 million during the quarter, compared to the consensus estimate of $516.61 million. During the same quarter in the prior year, the company earned $0.21 EPS. The company’s revenue was up 17.4% on a year-over-year basis. On average, research analysts forecast that Privia Health Group, Inc. will post 0.14 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Great Lakes Advisors LLC purchased a new position in shares of Privia Health Group during the 3rd quarter valued at approximately $4,487,000. Advantage Alpha Capital Partners LP bought a new stake in shares of Privia Health Group in the second quarter worth $3,941,000. Hsbc Holdings PLC increased its stake in shares of Privia Health Group by 69.2% in the second quarter. Hsbc Holdings PLC now owns 113,718 shares of the company’s stock worth $2,549,000 after buying an additional 46,526 shares during the last quarter. Edgestream Partners L.P. acquired a new stake in Privia Health Group in the second quarter valued at $2,209,000. Finally, ArrowMark Colorado Holdings LLC bought a new position in Privia Health Group during the 3rd quarter valued at $8,750,000. Institutional investors and hedge funds own 94.48% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Canaccord Genuity Group raised their target price on shares of Privia Health Group from $34.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Weiss Ratings reissued a “hold (c)” rating on shares of Privia Health Group in a research report on Monday, December 29th. Citigroup decreased their price target on Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, March 3rd. Wolfe Research set a $31.00 price objective on shares of Privia Health Group in a research report on Tuesday, January 6th. Finally, Piper Sandler reiterated an “overweight” rating and set a $36.00 price objective on shares of Privia Health Group in a research note on Thursday, February 26th. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Privia Health Group currently has an average rating of “Moderate Buy” and a consensus price target of $31.00.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.